GAMMAR IV 或安慰剂治疗慢性炎症性脱髓鞘性多发性神经病 (CIDP)-猫眼课题宝

GAMMAR IV 或安慰剂治疗慢性炎症性脱髓鞘性多发性神经病 (CIDP)

批准号：

5225586

负责人：

PETER DONOFRIO

金额：

$0.0万

依托单位：

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/5225586

关键词：

chronic disease /disorder clinical research clinical trials gamma globulin human subject human therapy evaluation immunotherapy intravenous administration myelinopathy nervous system disorder chemotherapy placebos polyneuritis

项目摘要

项目成果

PETER DONOFRIO的其他基金

相似基金

相关文献

中文摘要

翻译

慢性炎性脱髓鞘性多发性神经病（CIDP）是一种免疫介导的运动障碍，占约20%，显然未确诊的神经病被送到三级护理中心。虽然他们的贡献尚不清楚，但据认为，细胞和体液免疫机制在 CIDP。以前在CIDP患者中观察到改善对其他IVIG治疗无反应。这种治疗更容易，比常规治疗风险更低。

英文摘要

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated motor disorder that accounts for approximately 20% of apparently undiagnosed neuropathies referred to tertiary care centers. Although their contributions are unclear, it is thought that both cellular and humoral immune mechanisms play a part in the etiology of CIDP. Improvement has been noted in CIDP patients previously unresponsive to other therapies with IVIG. This treatment is easier and less risky than customary treatments.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文